Fenwick Represents Axiom in $15M Series Seed Funding - fenwick.com

Fenwick represented Axiom, a biotech company building AI models to predict the toxicity of drug candidates, in its $15 million Series Seed funding. The round included participation from Amplify Partners, Dimension Capital, and Zetta Venture Partners. Axiom will use the funds to continue to focus on predicting liver toxicity. More information can be obtained here. The Fenwick transaction team was led by corporate partners Michael Brown and Chance Goldberg and included associates Joon Kim, Teresa Anselmo-Thai and Bradley Shepard. Related Insights Events Seattle Tech Week 2025 July 03, 2025 Experience Fenwick Represents Arine in $30M Series C Funding June 24, 2025 Experience Fenwick Represents Ellipsis Health in $45M Funding Round June 13, 2025 Experience Fenwick Represents Akido Labs in $60M Series B Funding May 15, 2025 Experience Fenwick Represents Clarium in $27M Series A Funding May 08, 2025 Experience Fenwick Represents Rad AI in $60M Series C Funding January 30, 2025 View more related insights